Recently, an implementation and technical validation of additional screening strategies for EGFR mutational status—such as the droplet digital PCR (ddPCR) assays or, more in general, the ultrasensitive PCR approaches as well as the NGS-based analytical assessment of the allele frequency of gene variants (VAF) [48,49,50]—using liquid biopsies or minimal cytological specimens from NSCLC patients may be helpful to identify a higher number of mutation-positive patients, providing predictive biomarkers of clinical behaviour. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.